BMRN BioMarin Pharma Gross Profit Rate

Official company branding of BioMarin Pharmaceutical Inc. (BMRN)

BioMarin Pharmaceutical (BMRN) revenues are based on the sales of Voxzogo and therapies for rare pathologies. The gross profit margin as a percentage of revenue clearly demonstrates the efficiency of this model, and 71.30 expresses the latest level of this metric. The lack of alternatives for gene products creates a lifelong medical dependence on the brand. Management is currently shifting its focus from early-stage research to the aggressive expansion of the commercial presence of orphan drugs.

BioMarin Pharmaceutical (BMRN): Gross Margin from 07/04/2022 to 11/20/2026

Financial and market metric breakdowns for biomarin.com (BMRN)

- market value and analyst target forecast:
Basic company analysis:BMRN BioMarin Pharmaceutical Inc.
Finished products of BioMarin Pharmaceutical

Gross margin determines the efficiency of direct cost management, reflecting the profit share from each unit of revenue. By analyzing the gross margin of a company, an investor assesses the business's ability to retain resources after covering production costs. The stability of this ratio confirms the issuer's market dominance and pricing power. For BioMarin Pharmaceutical (BMRN), this metric depends critically on scaling Voxzogo sales and optimizing production costs for orphan drugs.